content_image/154753.jpg content_image/154751.jpg content_image/154752.jpg
## Building a long-term pipeline 

Cumberland is committed to identifying and nurturing early stage product candidates through its majority-owned subsidiary, Cumberland Emerging Technologies (CET). Established in partnership with Vanderbilt University and Launch Tennessee, CET bridges the development gap between the research laboratory and the commercial marketplace by providing researchers, universities and entrepreneurs with a commercial development infrastructure for promising biomedical technologies. 

CET partners with leading academic research centers throughout the mid-south region of the United States to evaluate emerging technologies with high commercial potential. By teaming with scientists to develop promising candidates, Cumberland is building a long-term pipeline while accelerating biomedical innovation. This strategy paved the way for the Company’s acquisition of ifetroban, which is currently being developed under the brand name Hepatoren, from CET in 2011. 

## CET Life Sciences Center 

<img src='content_image/154753.jpg'>

In May, Cumberland and China’s Gloria Pharmaceuticals made a combined $2 million investment in CET as part of a joint research and development initiative. The funds will be used to accelerate development of CET’s pipeline of new product candidates emerging from Vanderbilt University and other regional research centers. Gloria Pharmaceuticals, which also serves as Cumberland’s commercial partner for Acetadote ® and Caldolor ®  in China, will have the first opportunity to negotiate a license to CET products for China while Cumberland will retain access to CET’s products for the rest of the world. 

<img src='content_image/154751.jpg'>

<img src='content_image/154752.jpg'>

In addition to its partnerships with leading academic research centers, CET fosters innovation through the CET Life Sciences Center, a business incubator facility that provides laboratory and office space, equipment and infrastructure to early-stage biomedical companies. Located in the heart of downtown Nashville and just minutes away from the Vanderbilt University medical research facilities, the recently expanded facility offers a collaborative setting to support other life sciences initiatives. 

